DB
EVOK

Danske Bank’s Evoke Pharma EVOK Stock Holding History

Danske Bank’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$10 – 1484
2024
Q3 		$10 Buy
+2
New +$11 ﹤0.01% 1527

Other funds holding EVOK

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Danske Bank's EVOK Position: Q4 2024 in Review

Danske Bank sold out of Evoke Pharma (EVOK) in Q4 2024, closing a stake of 2 shares — an estimated $10 sold.

Danske Bank first reported a position in EVOK in Q3 2024 and held it in 1 quarter. The position peaked at $10 in Q3 2024. 8 funds tracked by Wall St. Rank hold EVOK as of Q4 2024.

  • Danske Bank reported no remaining Evoke Pharma position as of Q4 2024 after selling out during the quarter.
  • Danske Bank sold 2 Evoke Pharma shares in Q4 2024, an estimated $10.
  • Danske Bank first reported a position in Evoke Pharma in Q3 2024 and held it in 1 quarter.
  • Danske Bank's Evoke Pharma position peaked at $10 in Q3 2024.
  • 8 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.